BUSINESS

Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry

By Shinya Saito February 4, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Quick Look: A wave of patent challenges is underway before anticipated Trazenta generic entry in late 2026. Their results could shape the timing and scope of competition, with a key ruling due on February 9. ----- Japanese generic makers have…

To read the full story

Generic Entry into DPP-4 Class Poised to Accelerate in 2026
January 7, 2026

BUSINESS

Nippon Shinyaku to Take Over UCB’s Fintepla in Japan from April
February 25, 2026
Opdivo-Yervoy Expands Label for Colorectal Cancer in South Korea
February 25, 2026
Daiichi Sankyo Taps Ex-Novartis CMO John Tsai as R&D Head
February 24, 2026
Shionogi to Absorb Torii in April 2027
February 24, 2026
Sumitomo, Partners Launch Malaria Vaccine Project Targeting Mid-2030s Approval
February 24, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…